Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024

Key Takeaway: SI-BONE, Inc. has announced it will report its financial results for the fourth quarter and full year of 2023 on February 26, 2024. Following the report, management will host a conference call to discuss the results. As a leader in surgical solutions for musculoskeletal disorders, SI-BONE has a substantial history, supporting numerous surgeons and conducting thousands of procedures backed by clinical evidence. Investors can access the live webcast on the company's website.
Price reaction · baseline $20.52 (2024-02-02 close) · clean, no other SIBN news in the window
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Scheduled financial results announcement indicates transparency and communication with investors.
  • SI-BONE is a leader in its field, having supported over 3,600 surgeons.
  • Successful track record with over 95,000 procedures demonstrates the effectiveness of their technologies.
  • Strong clinical evidence with multiple randomized controlled trials enhances credibility.

Full Press Release Details

SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Monday, February 26, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/qe3y86y3. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 125 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its financial results?

SI-BONE will announce its financial results on February 26, 2024.

How can investors access the conference call?

Investors can register for the call at the provided link or via the SI-BONE website.

What has SI-BONE pioneered in its field?

SI-BONE pioneered minimally invasive surgery of the SI joint in 2009.

How many sacropelvic procedures has SI-BONE supported?

SI-BONE has supported over 95,000 sacropelvic procedures.

Where can I find more information about SI-BONE?

More information is available on SI-BONE's website at www.si-bone.com.

Last updated: Feb 5, 2024